Cargando…

Precision Medicine in Hormone Receptor-Positive Breast Cancer

In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasrazadani, Azadeh, Thomas, Roby A., Oesterreich, Steffi, Lee, Adrian V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945817/ https://www.ncbi.nlm.nih.gov/pubmed/29780747 http://dx.doi.org/10.3389/fonc.2018.00144

Ejemplares similares

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)

Network-guided prediction of aromatase inhibitor response in breast cancer
por: Ruffalo, Matthew, et al.
Publicado: (2019)

Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women
por: Carleton, Neil, et al.
Publicado: (2022)

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
por: Demas, Diane M., et al.
Publicado: (2019)

Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer
por: Meehan, James, et al.
Publicado: (2020)

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
por: Reinert, Tomas, et al.
Publicado: (2017)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Artificial intelligence-directed prognostication of breast cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2019)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
por: Scherer, Sandra D., et al.
Publicado: (2021)

26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3–6 December 2003: update on preclinical and translational research
por: Lee, Adrian V, et al.
Publicado: (2004)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression
por: Watters, Rebecca J, et al.
Publicado: (2012)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
por: Ran, Ran, et al.
Publicado: (2022)

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
por: Cescon, David W., et al.
Publicado: (2022)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021)

Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
por: Umemneku-Chikere, Chinyereugo M., et al.
Publicado: (2022)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
por: Alaklabi, Sabah, et al.
Publicado: (2022)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Global Inequities in Precision Medicine and Molecular Cancer Research
por: Drake, Thomas M., et al.
Publicado: (2018)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
por: Zhang, Jian, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
por: Marks, Douglas K., et al.
Publicado: (2020)

The role of IL-35 and IL-37 in breast cancer – potential therapeutic targets for precision medicine
por: Ma, Yuntao, et al.
Publicado: (2022)

RET signaling in breast cancer therapeutic resistance and metastasis
por: Pecar, Geoffrey, et al.
Publicado: (2023)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression
por: Saha, Suryendu, et al.
Publicado: (2021)

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
por: Wu, Zhen-Yu, et al.
Publicado: (2021)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
por: Ramroop, Johnny R., et al.
Publicado: (2018)

A New Era of Prostate Cancer Precision Medicine
por: Malik, Adil, et al.
Publicado: (2019)

Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine
por: Wang, Wanyan, et al.
Publicado: (2021)

Radiomics-Guided Precision Medicine Approaches for Colorectal Cancer
por: Quraishi, Mohammed I.
Publicado: (2022)

Editorial: Radiomics-based theranostics in cancer precision medicine
por: Ji, Jiansong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c9mjsumspa8tqkaho4oj4i5n39